RT Journal Article
SR Electronic
T1 Reinfection with SARS-CoV-2 and Failure of Humoral Immunity: a case report
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.22.20192443
DO 10.1101/2020.09.22.20192443
A1 Jason D. Goldman
A1 Kai Wang
A1 Katharina Röltgen
A1 Sandra C. A. Nielsen
A1 Jared C. Roach
A1 Samia N. Naccache
A1 Fan Yang
A1 Oliver F. Wirz
A1 Kathryn E. Yost
A1 Ji-Yeun Lee
A1 Kelly Chun
A1 Terri Wrin
A1 Christos J. Petropoulos
A1 Inyoul Lee
A1 Shannon Fallen
A1 Paula M. Manner
A1 Julie A. Wallick
A1 Heather A. Algren
A1 Kim M. Murray
A1 Yapeng Su
A1 Jennifer Hadlock
A1 Joshua Jeharajah
A1 William R. Berrington
A1 George P. Pappas
A1 Sonam T. Nyatsatsang
A1 Alexander L. Greninger
A1 Ansuman T. Satpathy
A1 John S. Pauk
A1 Scott D. Boyd
A1 James R. Heath
YR 2020
UL http://medrxiv.org/content/early/2020/09/25/2020.09.22.20192443.abstract
AB Recovery from COVID-19 is associated with production of anti-SARS-CoV-2 antibodies, but it is uncertain whether these confer immunity. We describe viral RNA shedding duration in hospitalized patients and identify patients with recurrent shedding. We sequenced viruses from two distinct episodes of symptomatic COVID-19 separated by 140 days in a single patient, to conclusively describe reinfection with a new strain harboring the spike variant D614G. With antibody and B cell analytics, we show correlates of adaptive immunity, including a differential response to D614G. Finally, we discuss implications for vaccine programs and begin to define benchmarks for protection against reinfection from SARS-CoV-2.Competing Interest StatementJDG and JRH received U.S. federal funding from Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201600031C, which is administered by Merck & Co. JDG performed contracted research with Gilead Sciences, Inc. ATS is a scientific founder of Immunai and receives research funding from Arsenal Biosciences. All other authors report no competing interests. The sponsor had no role in any stage of the study, including manuscript preparation, but reviewed the manuscript prior to submission.Funding StatementThis project has been funded with support from the Murdock Charitable Trust (JRH), the Jeff and Liesl Wilke Foundation (JRH), the Swedish Medical Center Foundation (JDG), the Coulter Foundation (SDB), and federal funds from the National Institutes of Health, National Institute of Allergy and Infectious Diseases, 3R01AI141953-02S1 (JRH), and from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201600031C, administered by Merck & Co (JRH, JDG).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Providence St. Joseph Health IRB approved the study (STUDY2020000175). Informed consent was waived for use of residual samples and population clinical data (STUDY2020000143).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be made public upon publication of the results in a peer-reviewed journal, as per our funding agreement with BARDA.